Literature DB >> 2895542

Microenvironment of thymic myoid cells in myasthenia gravis.

T Kirchner1, F Hoppe, B Schalke, H K Müller-Hermelink.   

Abstract

The microenvironment of myoid cells (MyCs) was studied in myasthenia gravis (MG) thymitis with lymphoid follicular hyperplasia (LFH) (nine cases) and with diffuse B cell infiltration (one case), and compared with findings in the thymuses of non-myasthenic control subjects (ten cases). Double immunostaining was used to demonstrate MyCs labelled by anti-desmin together with other thymic components such as keratin-positive epithelial cells, Ki-M 1-positive interdigitating reticulum cells (IDCs), Ki-M 4-positive follicular dendritic reticulum cells, Ki-M 6-positive macrophages, CD22-positive B-cells, CD1-positive cells, CD3-positive T-cells or HLA-DR-positive cells. Round or elongated MyCs were confined to the thymic medulla and were surrounded by CD3-positive T-cells and CD22-positive B-cells. In MG thymitis MyCs were localized in the vicinity of, but not inside germinal centres (GCs). MyCs were always HLA-DR-negative, but were invariably embedded in a cellular micromilieu with strong HLA-DR expression. A remarkable feature of MG thymitis was that the great majority of MyCs were in intimate contact with intramedullary IDCs. Morphometric studies confirmed that such contacts were significantly less frequent in thymuses from non-myasthenic subjects. This indicates that an IDC-dependent antigen-presenting process for T-cells may actively involve MyCs in MG thymitis.

Entities:  

Mesh:

Year:  1988        PMID: 2895542     DOI: 10.1007/bf02899226

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  9 in total

Review 1.  Do self-perpetuating B lymphocytes drive human autoimmune disease?

Authors:  J C Edwards; G Cambridge; V M Abrahams
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  Granzyme B: evidence for a role in the origin of myasthenia gravis.

Authors:  L Casciola-Rosen; A Miagkov; K Nagaraju; F Askin; L Jacobson; A Rosen; D B Drachman
Journal:  J Neuroimmunol       Date:  2008-08-03       Impact factor: 3.478

3.  The thymus in seronegative myasthenia gravis patients.

Authors:  N Willcox; M Schluep; M A Ritter; J Newsom-Davis
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

4.  Association of nerve fibres with myoid cells in the chick thymus.

Authors:  A S Chan
Journal:  J Anat       Date:  1992-12       Impact factor: 2.610

Review 5.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

6.  Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis.

Authors:  S Schönbeck; F Padberg; R Hohlfeld; H Wekerle
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

7.  The cardiac isoform of alpha-actin in regenerating and atrophic skeletal muscle, myopathies and rhabdomyomatous tumors: an immunohistochemical study using monoclonal antibodies.

Authors:  Roland Moll; Hans-Jürgen Holzhausen; Hans-Dieter Mennel; Caecilia Kuhn; Renate Baumann; Christiane Taege; Werner W Franke
Journal:  Virchows Arch       Date:  2006-05-20       Impact factor: 4.064

8.  Myogenesis in thymic transplants in the severe combined immunodeficient mouse model of myasthenia gravis. Differentiation of thymic myoid cells into striated muscle cells.

Authors:  S Spuler; A Marx; T Kirchner; R Hohlfeld; H Wekerle
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

9.  Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.

Authors:  M W Nicolle; B Nag; S D Sharma; N Willcox; A Vincent; D J Ferguson; J Newsom-Davis
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.